International Journal of Hematology and Oncology
2023, Vol 33, Num 4 Page(s): 199-206
EVALUATION OF CHILDREN WITH OSTEOSARCOMA AND MESENCHYMAL CHONDROSARCOMA
ÖMER GÖRGÜN1, İNCİ AYAN1, REJİN KEBUDİ1, GÜLNUR TOKU1, HARZEM ÖZGER1, FERHAN AKİCİ1, BİLGE BİLGİ1, VAKUR OLGA1, EMİN DARENDELİLER1
İstanbul Üniversitesi Onkoloji Enstitüsü Pediatrik Onkoloji Bilim Dalı
Keywords: osteosarcoma, chemotherapy, prognostic factors
Between September 1989 and February 1999, 57 patients with osteosarcoma or mesenchymal chondrosarcoma of bone were treated in the University of İstanbul, Institute of Oncology. These patients (33 male, 24 female), aged between 5-16 years (median 13), consisted of 49 osteosarcomas and 8 mesenchymal chondrosarcomas. The location of the tumor at presentation was femur in 25 (%44), tibia in 13 (%23), fibula in 5 (%9), humerus in 4 (%7), vertebra, pubis, ulna and mandibula in 2 each (%4), radius and temporo-parietal in 1 each (%2). Patients received three courses of chemotherapy before and three after surgery that consisted of epirubicin (90 mg/m2 day1), ifosfamide (1,8 g/m2 daily for three consecutive days) and cisplatin (100 mg/m2 day 4). Of 57 patients, 10 (%17) were metastatic at diagnosis and 47 (%83) were localised. Thirty-three of them (%58) had limb-salvage surgery, 6 (%10) amputation after neo-adjuvant chemotherapy, 4 (%7) amputation at presentation. Fourteen didnÕt undergo surgery for various reasons. Radiotherapy ranging 1000-5000 cGy was given to 14 patients for palliating pain or the positive surgical margins. Three year overall and event free survival were 60% and 46% respectively with a median follow-up of 18 months (1-100 months).
ÖMER GÖRGÜN1, İNCİ AYAN1, REJİN KEBUDİ1, GÜLNUR TOKU1, HARZEM ÖZGER1, FERHAN AKİCİ1, BİLGE BİLGİ1, VAKUR OLGA1, EMİN DARENDELİLER1
İstanbul Üniversitesi Onkoloji Enstitüsü Pediatrik Onkoloji Bilim Dalı
Keywords: osteosarcoma, chemotherapy, prognostic factors
Between September 1989 and February 1999, 57 patients with osteosarcoma or mesenchymal chondrosarcoma of bone were treated in the University of İstanbul, Institute of Oncology. These patients (33 male, 24 female), aged between 5-16 years (median 13), consisted of 49 osteosarcomas and 8 mesenchymal chondrosarcomas. The location of the tumor at presentation was femur in 25 (%44), tibia in 13 (%23), fibula in 5 (%9), humerus in 4 (%7), vertebra, pubis, ulna and mandibula in 2 each (%4), radius and temporo-parietal in 1 each (%2). Patients received three courses of chemotherapy before and three after surgery that consisted of epirubicin (90 mg/m2 day1), ifosfamide (1,8 g/m2 daily for three consecutive days) and cisplatin (100 mg/m2 day 4). Of 57 patients, 10 (%17) were metastatic at diagnosis and 47 (%83) were localised. Thirty-three of them (%58) had limb-salvage surgery, 6 (%10) amputation after neo-adjuvant chemotherapy, 4 (%7) amputation at presentation. Fourteen didnÕt undergo surgery for various reasons. Radiotherapy ranging 1000-5000 cGy was given to 14 patients for palliating pain or the positive surgical margins. Three year overall and event free survival were 60% and 46% respectively with a median follow-up of 18 months (1-100 months).